Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23178529 | 0.79 | LRRK2 (0.44) | LRRK2TLR8BRAFGAASMN1; SMN2 | |
| SCHEMBL24908111 | 0.78 | LRRK2 (0.43) | LRRK2TLR8BRAFGAASMN1; SMN2 | |
| SCHEMBL21087625 | 0.78 | LRRK2 (0.43) | LRRK2TLR8BRAFGAASMN1; SMN2 | |
| SCHEMBL24908096 | 0.75 | LRRK2 (0.46) | LRRK2TLR8DRD2DRD4DRD3 | |
| SCHEMBL21087790 | 0.73 | LRRK2 (0.40) | LRRK2TLR8GAASMN1; SMN2ALOX15 | |
| SCHEMBL24908061 | 0.73 | LRRK2 (0.40) | LRRK2TLR8BRAFGAASMN1; SMN2 | |
| SCHEMBL23152877 | 0.72 | HTR2A (0.43) | LRRK2TLR8 | |
| SCHEMBL21266847 | 0.68 | GAA (0.45) | LRRK2TLR8BRAFGAASMN1; SMN2 | |
| SCHEMBL24908253 | 0.68 | — | — | |
| SCHEMBL20067663 | 0.68 | ALOX15 (0.44) | GAASMN1; SMN2ALOX15IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027026-A1 | FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027026-A1 | FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | DPYD, TYMP, TYMS | LRRK2 1579/4885TLR8 4461/4885BRAF 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.